Holly B. Kordasiewicz, serving as Executive Vice President and Chief Development Officer at Ionis Pharmaceuticals Inc. (NASDAQ: IONS), executed a significant sale of company stock on June 12, 2026. According to a Form 4 filing submitted to the Securities and Exchange Commission, Kordasiewicz sold a total of 60,846 shares of common stock. The aggregate value of these transactions reached approximately $4.47 million.
The shares were sold at prices ranging from $72.68 to $74.28 per share. The transactions were carried out in multiple blocks, with weighted average prices recorded at $73.0934 and $74.0503 for the respective groups. These sales were executed pursuant to a Rule 10b5-1 trading plan, which Kordasiewicz adopted on March 13, 2026. This pre-arranged plan allows for automated stock sales regardless of market conditions, providing a structured approach to equity liquidation.
Immediately prior to the sale, Kordasiewicz acquired a total of 60,846 shares of Ionis Pharmaceuticals common stock through the exercise of stock options on the same date. These acquisitions occurred at prices ranging from $32.60 to $60.89 per share, totaling approximately $3.28 million. Following these combined transactions, Kordasiewicz directly owns 22,458 shares of Ionis Pharmaceuticals common stock.
The timing of this executive sale coincides with a period of significant movement in Ionis stock performance. Data from InvestingPro indicates that the stock has surged over 102% in the past year. The stock currently trades at $73.09. Despite the strong performance, InvestingPro analysis suggests that the shares may be overvalued at current levels. For deeper insights into IONS valuation and access to exclusive ProTips, visit the comprehensive Pro Research Report available on InvestingPro.
In other recent developments, Ionis Pharmaceuticals announced that its partner Biogen will advance the Alzheimer’s drug diranersen to registrational development. This decision follows the Phase 2 CELIA study results involving 416 participants with early Alzheimer’s disease. Additionally, Ionis Pharmaceuticals has raised its full-year 2026 revenue guidance to a range of $875 million to $900 million, up from the previous range of $800 million to $825 million.
Market analysts have responded to these developments with adjusted price targets. Oppenheimer raised its price target for Ionis to $110, maintaining an Outperform rating. H.C. Wainwright reiterated a Buy rating and set a $125 price target for Ionis Pharmaceuticals after positive Phase 3 data from GlaxoSmithKline’s hepatitis B treatment. The study showed a 19% functional cure rate in the overall chronic hepatitis B population. Wolfe Research maintained an Outperform rating with a $98 price target, noting the significance of upcoming data from Arrowhead Pharmaceuticals.
Ionis Pharmaceuticals also appointed Ludwig Hantson to its board of directors, bringing over 30 years of industry experience. The stock experienced a -0.87 (-1.18%) change, closing at $73.09 as of 15:59:59 USD. After hours trading at 17:24:45 showed no change, with the price remaining at $73.09.
Key Points:
- Executive Stock Sales: Holly Kordasiewicz sold 60,846 shares worth $4.47 million under a Rule 10b5-1 plan, a standard practice for structured equity management.
- Revenue and Clinical Advances: Ionis raised its 2026 revenue guidance to $875-$900 million and announced the advancement of diranersen to registrational development following positive Phase 2 data.
- Analyst Sentiment: Analysts from Oppenheimer, H.C. Wainwright, and Wolfe Research have maintained positive ratings, citing clinical progress and adjusting price targets upward.
Risks and Uncertainties:
- Valuation Concerns: Despite positive catalysts, some analysis suggests the stock may be overvalued at current levels, indicating potential volatility.
- Clinical Trial Dependencies: The advancement of diranersen and other programs depends on future Phase 3 data, which could impact stock performance if results do not meet expectations.
- Market Sensitivity: The stock's significant surge over the past year may lead to profit-taking or increased sensitivity to short-term market fluctuations.
Tags: IONS, Biotech, Insider Trading, Revenue Guidance, Clinical Trials